Olema Oncology to Participate at Upcoming Investor Conferences

Rhea-AI Summary

Olema Pharmaceuticals, a clinical-stage biopharmaceutical company focused on women’s cancers, is set to present at two investor conferences. Sean Bohen, M.D., will engage in a fireside chat at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 12:00 p.m. ET. Additionally, Shane Kovacs will participate in the Breast and Lung Cancer Corporate Panel at Cowen’s 43rd Annual Healthcare Conference on March 7, 2023, at 10:30 a.m. ET in Boston, MA. A live webcast of these events will be available on Olema’s Investor Relations website and archived for 30 days. Olema's lead candidate, OP-1250, is an FDA Fast Track designated drug for ER-positive breast cancer.

SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company will present at the following upcoming investor conferences:

• Sean Bohen, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at Citi’s 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 12:00 p.m. ET.
  
• Shane Kovacs, Chief Operating and Financial Officer, will participate in the Breast and Lung Cancer Corporate Panel at Cowen’s 43^rd Annual Healthcare Conference on Tuesday, March 7, 2023, at 10:30 a.m. ET in Boston, MA.
  

A live webcast of these events will be available under the News & Events section of Olema’s Investor Relations website at www.olema.com and will be archived for at least 30 days.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. 

IR Contact:
Courtney Dugan, Vice President, Investor Relations and Communications
ir@olema.com

Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
ignacio.guerrero-ros@russopartnersllc.com

FAQ

What investor conferences will Olema Pharmaceuticals present at?

Olema Pharmaceuticals will present at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, and Cowen’s 43rd Annual Healthcare Conference on March 7, 2023.

Who will represent Olema Pharmaceuticals at the Citi Virtual Oncology Leadership Summit?

Sean Bohen, M.D., President and CEO of Olema Pharmaceuticals, will participate in the Citi Virtual Oncology Leadership Summit.

What is the significance of OP-1250 for Olema Pharmaceuticals?

OP-1250 is Olema's lead product candidate, which has dual activity against estrogen receptors and has received FDA Fast Track designation for treating ER-positive breast cancer.

When will the Cowen Healthcare Conference take place?

The Cowen’s 43rd Annual Healthcare Conference will be held on March 7, 2023, with Shane Kovacs representing Olema Pharmaceuticals.

How can investors watch Olema Pharmaceuticals' conference presentations?

Investors can watch a live webcast of Olema Pharmaceuticals' conference presentations on the Investor Relations section of their website.